Prevail Therapeutics’ (PRVL) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Prevail Therapeutics (NASDAQ:PRVL) in a report released on Wednesday, 24/7 WallStreet reports.

A number of other equities research analysts have also recently commented on PRVL. Bank of America initiated coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued a buy rating and a $15.00 target price on the stock. Morgan Stanley initiated coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an overweight rating and a $20.00 target price on the stock. Finally, Cowen initiated coverage on Prevail Therapeutics in a research note on Monday, July 15th. They issued an outperform rating on the stock.

PRVL traded up $0.93 during trading on Wednesday, reaching $11.70. The stock had a trading volume of 58,960 shares, compared to its average volume of 46,133. The firm’s 50 day simple moving average is $10.83. The company has a current ratio of 26.94, a quick ratio of 26.94 and a debt-to-equity ratio of 0.04. Prevail Therapeutics has a one year low of $7.41 and a one year high of $16.90.

Prevail Therapeutics (NASDAQ:PRVL) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.66. On average, analysts predict that Prevail Therapeutics will post -2.53 EPS for the current year.

In related news, Director Carl L. Gordon bought 882,352 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were purchased at an average cost of $17.00 per share, with a total value of $14,999,984.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blackstone Group Inc purchased a new stake in shares of Prevail Therapeutics in the second quarter worth $66,000. Point72 Hong Kong Ltd purchased a new stake in shares of Prevail Therapeutics in the second quarter worth $106,000. Morgan Stanley purchased a new stake in shares of Prevail Therapeutics in the second quarter worth $166,000. Northern Trust Corp purchased a new stake in shares of Prevail Therapeutics in the second quarter worth $188,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Prevail Therapeutics in the second quarter worth $194,000. 77.49% of the stock is currently owned by hedge funds and other institutional investors.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Article: Does the discount rate affect the economy?

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.